Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04630769
Title FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota

peritoneum cancer

fallopian tube cancer

ovary epithelial cancer


Aldesleukin + FT516

Aldesleukin + FT516 + MGA271

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.